Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 13/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18172571 | 0.94 | KDM1A (0.58) | KDM1AKDM4EPKMGPR119 | |
| SCHEMBL18172574 | 0.94 | KDM1A (0.58) | KDM1AKDM4EPKMGPR119 | |
| SCHEMBL20527608 | 0.94 | KDM1A (0.58) | KDM1AKDM4EPKMGPR119 | |
| SCHEMBL18172568 | 0.94 | KDM1A (0.58) | KDM1AKDM4EPKMGPR119 | |
| SCHEMBL18172565 | 0.94 | KDM1A (0.58) | KDM1AKDM4EPKMGPR119 | |
| SCHEMBL21049154 | 0.88 | KDM1A (0.66) | KDM1AGPR119 | |
| SCHEMBL25923730 | 0.88 | KDM1A (0.66) | KDM1AGPR119 | |
| SCHEMBL21049156 | 0.88 | KDM1A (0.66) | KDM1AGPR119 | |
| SCHEMBL18182495 | 0.88 | KDM1A (0.66) | KDM1AGPR119 | |
| SCHEMBL18183160 | 0.87 | KDM1A (0.61) | KDM1AKDM4EPKMGPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3532459-B1 | LSD1 INHIBITORS AND MEDICAL USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11547695-B2 | LSD1 inhibitors and medical uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11013718-B2 | LSD1 inhibitors and medical uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200306223-A1 | LSD1 INHIBITORS AND MEDICAL USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2020-10-01 | — | — | US | disclosed |
| US-10517849-B2 | LSD1 inhibitors and medical uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190274998-A1 | LSD1 INHIBITORS AND MEDICAL USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| EP-3286172-B1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| WO-2018081343-A1 | LSD1 INHIBITORS AND MEDICAL USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11547695-B2 | LSD1 inhibitors and medical uses thereof | KDM1B, KDM1A, KDM2A | KDM1A 2/4885KDM4E 25/4885PKM 388/4885 |
| US-20200306223-A1 | LSD1 INHIBITORS AND MEDICAL USES THEREOF | KDM1B, KDM1A, KDM2A | KDM1A 2/4885KDM4E 25/4885PKM 388/4885 |
| US-10517849-B2 | LSD1 inhibitors and medical uses thereof | KDM1B, KDM1A, KDM2A | KDM1A 2/4885KDM4E 25/4885PKM 388/4885 |
| US-11013718-B2 | LSD1 inhibitors and medical uses thereof | KDM1B, KDM1A, KDM2A | KDM1A 2/4885KDM4E 25/4885PKM 388/4885 |
| US-20190274998-A1 | LSD1 INHIBITORS AND MEDICAL USES THEREOF | KDM1B, KDM1A, KDM2A | KDM1A 2/4885KDM4E 25/4885PKM 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.